Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on September 2, 2026 reporting Item EX-99.1 (Exhibit EX-99.1). Six-month revenue $29.3M versus $74.7M operating expenses, producing a $41.2M net loss.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Six-month revenue $29.3M versus $74.7M operating expenses, producing a $41.2M net loss
- $23.6M impairment charges and $19.7M credit losses signal substantial deterioration in royalty-asset valuations and expected collections
- Cash, equivalents, and restricted cash $150.6M, including $51.3M restricted, limiting freely deployable liquidity
- Long-term debt $89.0M plus $14.1M current maturities, with $6.2M interest expense creating ongoing cash obligations
- Revenue concentration risk: three partners generated 43%, 37%, and 16% of six-month income and revenues
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.